Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders





All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other

Tags
Quarterly results
Director departure
Appointed director
Inv. presentation
Acq. completed
Consulting agrmnt
Employment agrmnt

Theriva Biologics, Inc. (SYN) Create: Alert

All | News | Filings
Date FiledTypeDescription
10/03/2023 8-K Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits  Interactive Data
08/16/2023 DEFR14A Form DEFR14A - Revised definitive proxy soliciting materials:
08/15/2023 ARS Form ARS - Annual Report to Security Holders:
08/14/2023 DEF 14A Form DEF 14A - Other definitive proxy statements:
08/11/2023 8-K Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits  ...
Docs: "STOCKHOLDERS"
08/08/2023 10-Q Quarterly Report for the period ended June 30, 2023
08/08/2023 8-K Quarterly results
Docs: "Theriva™ Biologics Reports Second Quarter 2023 Operational Highlights and Financial Results"
08/02/2023 8-K Quarterly results
05/11/2023 10-Q Quarterly Report for the period ended March 31, 2023
05/11/2023 8-K Quarterly results
Docs: "Theriva Biologics Reports First Quarter 2023 Operational Highlights and Financial Results"
03/30/2023 10-K Annual Report for the period ended December 31, 2022
03/30/2023 8-K Quarterly results
03/10/2023 8-K Non-Reliance on Previously Issued Financial Statements or a Related Audit Report or Completed Interim Review, Other Events, F...
01/17/2023 8-K Quarterly results
01/09/2023 8-K Quarterly results
12/23/2022 8-K Quarterly results
12/20/2022 8-K Quarterly results
12/09/2022 EFFECT Form EFFECT - Notice of Effectiveness:
12/05/2022 424B5 Form 424B5 - Prospectus [Rule 424(b)(5)]:
12/05/2022 POS AM Form POS AM - Post-Effective amendments for registration statement:
10/17/2022 S-8 Form S-8 - Securities to be offered to employees in employee benefit plans:
10/12/2022 8-K Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Regulation FD Disclosure, Other Events, Financial S...
Docs: "Certificate of Change to Articles of Incorporation",
"Amended and Restated Bylaws",
"Synthetic Biologics Rebrands as Theriva Biologics"
10/03/2022 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
09/30/2022 8-K Quarterly results
09/27/2022 8-K Regulation FD Disclosure, Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Synthetic Biologics Announces Positive Outcome of Data and Safety Monitoring Committee Review in Phase 1b/2a Clinical Trial of SYN-004 in Allogeneic Hematopoietic Cell Transplant Recipients"
09/16/2022 424B3 Form 424B3 - Prospectus [Rule 424(b)(3)]:
09/15/2022 EFFECT Form EFFECT - Notice of Effectiveness:
09/12/2022 8-K Other Events, Financial Statements and Exhibits  Interactive Data
09/06/2022 S-3 Form S-3 - Registration statement under Securities Act of 1933:
09/06/2022 8-K/A Financial Statements and Exhibits  Interactive Data
Docs: "Synthetic Biologics, Inc. and Subsidiaries Unaudited Pro Forma Condensed Combined Financial Statements for the six months ended June 30, 2022"
09/06/2022 8-K Regulation FD Disclosure, Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Synthetic Biologics Announces Presentation at ESMO Congress 2022 Describing Phase 1 Investigator-sponsored Study Evaluating VCN-01 in Combination with Durvalumab in Patients with Recurrent/ Metastatic Squamous Cell Carcinoma of the Head and Neck"
08/16/2022 DEF 14A Form DEF 14A - Other definitive proxy statements:
08/11/2022 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
08/11/2022 10-Q Quarterly Report for the period ended June 30, 2022
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy